Alzheimer's disease (AD) is characterized by memory loss, insidious cognitive decline, profound neurodegeneration and the extracellular accumulation of amyloid-beta (Aβ) peptide in senile plaques and intracellular accumulation of tau in neurofibrillary tangles. Loss and dysfunction of synapses are believed to underlie the devastating cognitive decline in AD. A large amount of evidence suggests that oligomeric forms of Aβ associated with senile plaques are toxic to synapses, but the precise sub-synaptic localization of Aβ and which forms are synaptotoxic remain unknown. Here, we characterize the sub-synaptic localization of Aβ oligomers using three high-resolution imaging techniques, stochastic optical reconstruction microscopy, immunogold electron microscopy and Förster resonance energy transfer in a plaque-bearing mouse model of Alzheimer's disease. With all three techniques, we observe oligomeric Aβ inside synaptic terminals. Further, we tested a panel of Aβ antibodies using the relatively highthroughput array tomography technique to determine which forms are present in synapses. Our results show that different oligomeric Aβ species are present in synapses and highlight the potential of array tomography for rapid testing of aggregation state specific Aβ antibodies in brain tissue.
Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disease associated with profound cognitive decline and memory dysfunction. Pathologically, the brains of patients are characterized by the presence of aggregated amyloid-beta (Aβ) in senile plaques, the intracellular accumulation of hyperphosphorylated tau in neurofibrillary tangles, and brain atrophy due to loss of neurons and synapses [1] . Of these pathological changes in AD brain, decreased connectivity between neurons due to synapse loss correlates most strongly with cognitive decline.
A large body of evidence supports a role for soluble amyloid-beta (Aβ) in synapse dysfunction and collapse [2] [3] [4] [5] [6] . Aβ, particularly in oligomeric form, facilitates long-term depression and inhibits long-term potentiation, both electrophysiological correlates of memory formation [7] [8] [9] .
Whether Aβ induces synapse loss directly by interaction with synaptic receptors or indirectly through interactions with intermediate molecules is not clear, it is therefore necessary to study these interactions at the synaptic level. However, synapses are too small to be visualized accurately using traditional light microscopy (including multiphoton and confocal imaging) due to the limitation of the axial (z) resolution. The array tomography technique developed by Micheva and Smith [10, 11] overcomes the z resolution limit by physically cutting fixed tissue samples into 70 nm serial sections. This enables the visualization of synapses and proteins of interest using standard immunofluorescence techniques. Using the oligomer-recognizing Aβ antibody NAB61 [12] on tissue prepared for array tomography, we previously demonstrated that oligomeric Aβ (oAβ) accumulates in a halo around the edges of plaques and colocalizes with a subset of synapses in wild-type and APPswe/PS1deltaE9 mice [13] . We further pioneered the use of array tomography for human postmortem tissue [14] and found that in human AD brain, oAβ is associated with a subset of small synapses near plaques, confirming the relevance of this pathway to human disease [15] .
Since the association of oAβ with synapses occurs most often in the halo of oligomers surrounding plaques, we assume that the synaptic oAβ derives from extracellular sources and binds to receptors in the synaptic cleft. Thus we expected that oAβ would bind the extracellular face of the pre and postsynaptic terminals, although data have been presented indicating that oAβ can enter cells through several mechanisms including direct permeabilization of the membrane by oAβ [16] and endocytosis [17] . The resolution of array tomography imaged with standard fluorescent microscopy is approximately 250 nm in the x-y plane, which does not allow accurate determination of whether oAβ is found in the synaptic cleft or within synapses with standard imaging techniques. Here we have examined whether NAB61-positive Aβ oligomers are found in the synaptic cleft or within the postsynapse using three high resolution imaging techniques: stochastic optical reconstruction microscopy (STORM), immunogold transmission electron microscopy (TEM), combined array tomography and Förster resonance energy transfer (FRET) imaging. All of these techniques indicate that oAβ is present within the postsynapse and further validate the use of array tomography for accurate localization of pathological proteins with synapses.
Following the validation of the array tomography technique for accurate colocalization of oAβ at synapses, we tested a panel of Aβ antibodies: the previously characterized monoclonal aggregate-preferring oAβ antibody (NAB61) which recognizes oligomers and fibrils but not monomers [12] , a monoclonal aggregate-selective antibody (1C22) [18] , a conformation-specific antibody known to detect fibrillar oAβ arranged in in-register parallel β sheets (OC) [19] [20] [21] and a polyclonal anti-Aβ antibody (AW7) which recognises multiple Aβ assemblies and epitopes, including monomeric Aβ40 and Aβ42 [22] . We explore to what extent these antibodies bind oAβ and recognise synapse-associated oAβ. Applying this array tomography approach in a transgenic AD mouse model (APP/PS1), we demonstrate that all four Aβ antibodies co-localize with a subset of postsynaptic densities and a subset of presynapses around plaques in APP/PS1 brain.
This study illustrates the power of array tomography for detecting pathological protein conformations at individual synapses, and confirms with multiple antibody probes that oAβ is present in synapses in a mouse model of AD.
Material and Methods

Animals
Brains from APP/PS1 (n=9) and wild-type (n=4) mice aged 8-12 months were used in this study.
At this age, APP/PS1 mice have discernible deficits in spatial reference memory [23] , substantial plaque pathology and well-established plaque associated synapse loss and synaptic Aβ accumulation [13, 24] . All animal experiments were performed in accordance with institutional and national ethics guidelines and approved by the Harvard Medical School Institutional Animal
Care and Use Committee and the UK Home Office.
STORM
Ultra-thin sections (70 nm) of APP/PS1 mouse brains were prepared from array tomographyembedded blocks as described below. Slides were incubated in fresh 0.1% (w/v) sodium borohydride (NaBH4) in PBS for 7 minutes to quench autofluorescence, blocked in 5% goat serum in PBS for 30 minutes, immunolabeled for PSD and oAβ ( STORM data acquisition was performed with a 100x oil immersion objective (Plan Apo VC 100x
1.4 oil) using a N-STORM microscope system (Nikon) equipped with perfect focus system, TIRF laser line for plane illumination, and an EM-CCD camera. To reduce the out-of-focus fluorescence, samples were first illuminated with 647 nm imaging laser at low intensity (laser power 1.5 mW), actual imaging cycles contained one frame of 561 nm activation laser (laser power ~0.03 mW) to activate a small fraction of reporter fluorophores followed by 3 frames of 647 nm imaging laser illumination (laser power ~150 mW). A total of 15000 frames were collected at 33 frames per second. STORM data was analyzed with ElementsV (Nikon) applying drift compensation, and allowing for a signal duration of 30 ms and a minimum of 500 photons counted per pixel (camera sensitivity = 0.18 photons per count). hours. Sections were washed in PBS as before, post-fixed in PBS containing 2.5%
Immunogold-TEM
glutaraldehyde, and counter stained with 3% uranyl acetate in 50% ethanol for 15 minutes followed by 4% lead citrate in a CO 2 free environment for 2.5 minutes. EM grids were imaged using a JEOL JEM-1011 transmission electron microscope with Hamamatsu ORCA digital camera (courtesy Marian DiFiglia and the Philly Dake Electron microscopy core). Synapses were defined by an electron dense postsynaptic density adjacent to a presynaptic terminal containing at least 3 synaptic vesicles. Apposition length was measured along the distance of the PSD facing the synaptic cleft of type 1 (putative excitatory) synapses.
FRET microscopy
For acceptor photobleaching FRET analysis [25] of NAB61 and postsynaptic marker PSD95 colocalization, array ribbons from APP/PS1 (n=5) and wild-type (n=4) mice were immunofluorescently labeled for oAβ using NAB61 and donkey anti-mouse Cy5 (acceptor secondary antibody) and for PSD using goat anti-PSD95 and rabbit anti-goat Cy3 (donor secondary antibody) as described previously [13, 15] . Briefly, array ribbons were rehydrated for 5 minutes in 50 mM glycine in 1X Tris-buffered saline (TBS) and placed in blocking buffer (0.05% Tween and 0.1% BSA in TBS) for 30 minutes. Ribbons were immunostained with primary antibodies against NAB61 and PSD95 (Table 1) 
Array tomography
Fresh brain tissue samples were collected from APP/PS1 transgenic mice as outlined previously [13, 14] . Briefly, small tissue blocks of four 8-12 month old APP/PS1 mice were fixed in 4% paraformaldehyde and 2.5% sucrose in 20 mM phosphate buffered saline pH7.4 (PBS) for 3
hours. Samples were then dehydrated through ascending cold graded ethanol and embedded into LR White resin (EMS) which was allowed to polymerize overnight at 53°C. Resin embedded tissue blocks were cut into array ribbons of 70 nm thick sections using an ultracut microtome (Leica) equipped with a Jumbo Histo Diamond Knife (Diatome, Hatfield, PA) and collected onto gelatin coated coverslips.
For immunolabeling of synapses and Aβ on "day 1", array ribbons were immunostained as described for FRET imaging with primary antibodies against NAB61 and PSD95 (Table 1) and fluorescently labeled secondary antibodies (Table 1) . Sections were counterstained with 0.01mg/mL 4'-6-diamidino-2-phenylindole (DAPI). For each area of interest, images were obtained on serial sections using a Zeiss axio Imager Z2 epifluorescent microscope at 63X
1.4NA Plan Apochromat objective with equipped CoolSnap digital camera and AxioImager software with array tomography macros (Carl Zeiss, Ltd, Cambridge UK).
Coverslips were removed from slides and washed. All primary and secondary antibodies were stripped for 15 minutes using stripping buffer (0.2 M NaOH 0.02% SDS in ddH20). The staining protocol was repeated as previously described for "day 1" with primary antibodies against 1C22, OC and PSD95 and appropriate secondary antibodies (Table 1) . Images were captured in the same location as the previous day using identifiable marked nuclei. Following "day 2" imaging the ribbons were once again stripped of all antibodies and stained with antibodies against AW7
and Synaptophysin for "day 3" (Table 1) . Images were obtained in the same location as both days 1 and 2 using specific nuclei as markers. Images from each set of serial sections across the three days were converted into image stacks and aligned using the Image J plug-in, MultiStackReg (courtesy of Brad Busse and P. Thevenaz, Stanford University) [26] . Cropped regions of interest (10 µm 2 ) around the plaque were generated. Amyloid-beta image stacks were then binarised using thresholding algorithms in ImageJ. For synaptic images stacks were binarised using an ImageJ script that combines different thresholding algorithms in order to select both high and low intensity synapses in an automated and unbiased manner.
Thresholded images were processed and analysed in MATLAB to remove background noise (objects present in only a single section were removed) and to calculate the colocalization of Aβ with both pre-and post-synapses. The % colocalization for each antibody combination from each mouse was calculated as the sum of the number of colocalization/sum total pre-or postsynapses. 
Statistical
Data Sharing:
Upon acceptance, all data used in this manuscript including custom image analysis scripts for
ImageJ and MATLAB will be freely shared on the University of Edinburgh Data Repository http://datashare.is.ed.ac.uk.
Results
STORM, TEM and FRET confirm presence of oAβ in the postsynaptic density
We have previously shown that oAβ recognised by NAB61 is associated with synaptic degeneration in the APP/PS1 mouse model and human AD patient brain [13, 15] . Here, we further specified the localization of these oAβ species applying several high-resolution imaging Immunogold labeling of NAB61 in APP/PS1 brain samples observed with TEM was used to determine further the precise subcellular localization of oAβ. We observe the most robust NAB61 staining in close proximity to plaque fibrils ( Figure 1C and Supplemental Figure 1 ) as expected from the intense plaque labeling with NAB61 in immunofluorescence studies. We also observed NAB61 immunogold labeling in both presynaptic and postsynaptic terminals ( Figure   1C ) confirming our immunofluorescence data showing NAB61 colocalization with synaptic staining in the neuropil. Notably, in synapses, the oAβ was not associated with fibrils, which are readily recognized by TEM ( Figure 1C) . None of the synapses observed across 4 mice (regardless of whether they were positive for NAB61) contained fibrils. This provides additional confirmation of the previous NAB61 characterization [12] as recognising oligomeric Aβ in addition to our observed fibril staining. NAB61 staining was not restricted to plaques and synapses. We also observe staining in cell bodies, dendrites, and mitochondria (Supplemental Figure 2) , which supports our array tomography immunofluorescence observations of NAB61 in some neuronal cell bodies and in punctae in the neuropil that are not positive for synaptic markers [13, 15] .
To determine whether oAβ is present inside PSDs, as indicated by colocalization with PSD95 punctae in array tomography sections, we performed FRET microscopy on these sections, which 
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Array tomography reveals synaptic staining with several markers of Aβ
To characterize the synaptic profile of four Aβ-specific antibodies; NAB61, 1C22, OC and AW7, we immunolabeled Aβ and synaptic markers in array tomography sections of APP/PS1 mouse brains (n=4 mice) in a three-day imaging protocol (Figure 3) . In each experiment, a small extra ribbon of sections was used as a stripping control with no primary antibodies applied on the subsequent day. Applying secondary antibodies after stripping confirmed effective stripping of antibodies on each day of staining (Supplemental Figure 3) .
We found that all four antibodies labeled plaques in APP/PS1 brains ( Figure 
Discussion
There is mounting evidence that oAβ plays a key role in synapse dysfunction and loss [27] .
Oligomeric Aβ modulates several intracellular pathways including activating caspase-3 and calcineurin at the synapse to ultimately culminate in synaptic failure [28] [29] [30] [31] . Synaptic dysfunction may precede cognitive decline in AD by several decades and could potentially be reversible [32] . In this study, we addressed two important remaining questions around oAβ−mediated synapse loss, namely is toxic oAβ located in the synaptic cleft or within presynaptic terminals and postsynaptic densities? And which forms of Aβ are associated with synapses?
Whether toxic Aβ at synapses originates from intracellular or extracellular sources is a hotly debated topic in the field [33] [34] [35] [36] . Here we used three high-resolution imaging techniques to examine whether oAβ is present within synaptic terminals or decorating the exterior membrane of pre and postsynapses and find that NAB61 labeled oAβ is present inside synapses. Our data suggest that synaptotoxic oAβ derives from the extracellular plaque halo since localization of Aβ at synapses occurs most often in this region [13, 15] , however it appears oAβ is present within synapses (Figures 1-2 ). This could occur alongside the internalization of synaptic receptors initiated by oAβ or more directly through the reported pores that Aβ can form in membranes [27, 37] . It is also worth noting, that while we specifically examined synapses in this study, we did observe oAβ in other subcellular compartments by TEM. We observed immunogold labelling associated with ribosomes in neuronal somata and dendrites, cell membrane staining, and mitochondrial staining (Supplemental Figure 2) . Mitochondrial staining is particularly interesting in light of the large body of literature supporting a role of oAβ in causing mitochondrial damage [38] Another contentious and important topic on the road to synapse-directed therapeutics is which specific forms of oAβ are toxic at synapses and therefore which would be the best targets. One recent study in mice classified oligomers in mice as type 1 (A11-immunoreactive, Aβ*56) and type 2 (recognized by OC) and concluded that type 2 oligomers were less toxic because of their containment within plaques [21] . Our data indicate that type 2 oligomers (OC positive) are present in synapses, where they may contribute to toxicity. In line with our observations, OC reactivity correlated with onset and severity of AD in human brain samples [39] , and synaptotoxic oligomers of Aβ that interact with PrP and inhibit LTP were also recognised by OC [40] .
Previous studies of colocalization of proteins within synapses were hampered by the difficulty of techniques such as immunogold EM, which are very low throughput and only allow one or two proteins of interest to be studied. Here we used the relatively high-throughput array tomography technique [14] which allowed us to examine the colocalization of four antibodies within the same pre and postsynaptic terminals. Array tomography is limited by the reliance on antibody staining of synaptic proteins and threshold-based image analyses, which does not guarantee accurate identification of synaptic puncta due to a combination of antibody specificity and analysis artifacts; however, a recent study using correlative array tomography and electron microscopy confirmed that ~98% of synapses in CA1 were accurately identified with array tomography staining [41] . This powerful technique will be useful since passive immunization with oAβ-specific antibodies is a promising potential treatment in AD, which could specifically reduce synaptic oAβ and reverse or prevent synapse loss. With multiple oAβ-specific antibodies being developed [42] [43] [44] [45] , it will be crucial to find effective ways to quickly validate these antibodies in brain tissue, be due to the relatively high affinity for AW7 staining fibrils. All antibodies tested labeled the plaque core to some extent, but AW7 stained fibrils very strongly. We postulate that if the antibodies have a high affinity for fibrils, they may have less opportunity to bind the less abundant synaptic Aβ, and the lower intensity synaptic staining may be below the detection level due to the bright staining of the fibrils in the same microscopic field.
Another important observation in this study is the association of Aβ with both pre and postsynaptic elements. Many of the studies of the synaptic effects of Aβ implicate postsynaptic mechanisms in synapse toxicity, but presynaptic mechanisms have also been found [27, 46] .
Our data show more Aβ at excitatory postsynapses than at presynaptic terminals consistent with the ideas that both pre and postsynapses are affected by Aβ and that postsynaptic processes are particularly important in synapse loss. Our data indicate that there is not likely a single synaptotoxic species of Aβ but instead multiple conformers are present inside pre and postsynaptic terminals near plaques. It is clear that Aβ-induced synaptic toxicity plays a major role in the pathogenesis of AD and that targeting synaptic pathology aiming at protecting or reversing synaptic damage is a promising avenue for developing disease-modifying treatments. Immunogold-TEM for NAB61 (C) shows 15 nm gold labeling of plaque fibrils (white arrows).
NAB61 is also observed in a subset of postsynapses (black arrow) and presynaptic terminals (arrowheads). Filaments were not observed in the synapses labeled with NAB61 indicating that a non-filamentous form of Aβ is present at synapses. Scale bars represent 5 µm in A, 1 µm in B, and 500 nm in C. 
26
